Concepedia

Author

Marco Mielcarek

Fred Hutch Cancer CenterORCID

Also Known As

Javier Meade, John Wagner, M Mielcarek, M. Mielcarek, MARCO MIELCAREK, Marco B. Mielcarek, Marco Mielcarek

192

Publications

9K

Citations

45

H-Index

58

Concepts

All Affiliations

Fred Hutch Cancer CenterUniversity of WashingtonCancer Research CenterUniversity of Washington Medical CenterCity Of Hope National Medical Center
MM

About

Marco Mielcarek is an author at Fred Hutch Cancer Center specializing in medicine, transplantation, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

17

1.2K

2

Health Sciences

5

5

407

3

Public Health

1

1

64

4

African American Studies

1

1

64

5

Allergy

1

1

65

Marco Mielcarek

×

80

Publications

8.5K

Citations

43

H-Index

YearCitations

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

Mary E.D. Flowers, Yoshihiro Inamoto, Paul A. Carpenter,

Blood

2011

668

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

Marco Mielcarek, Paul J. Martin, Wendy M. Leisenring,

Blood

2003

555

Cord-Blood Transplantation in Patients with Minimal Residual Disease

Filippo Milano, Ted Gooley, Brent L. Wood,

New England Journal of Medicine

2016

429

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?

Daisuke Araki, Brent L. Wood, Megan Othus,

Journal of Clinical Oncology

2015

385

Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning

Frédéric Baron, Michael B. Maris, Brenda M. Sandmaier,

Journal of Clinical Oncology

2005

333

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

Mohamed L. Sorror, Brenda M. Sandmaier, Barry E. Storer,

JAMA

2011

315

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

Margaret L. Green, Wendy M. Leisenring, Hu Xie,

Blood

2013

304

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Javier Bolaños‐Meade, Ran Reshef, Raphael Fraser,

The Lancet Haematology

2019

274

Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

Christopher G. Kanakry, Paul V. O’Donnell, Terry Furlong,

Journal of Clinical Oncology

2014

271

Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts

George B. McDonald, Brenda M. Sandmaier, Marco Mielcarek,

Annals of Internal Medicine

2020

259

Page 1